SOST Antibody Formulation Stability via Acetate Buffer and Trehalose
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-bone resorption drugs for osteoporosis fail to reconstruct lost bones and improve bone microstructure, while existing anabolic drugs have limitations such as short-lasting effects, high cost, and safety concerns, highlighting the need for stable and effective pharmaceutical compositions targeting sclerostin for enhanced bone metabolism regulation.
Innovation Solution
A pharmaceutical composition comprising anti-SOST antibodies or antigen-binding fragments, formulated with specific concentrations of acetate buffer, trehalose, polysorbate 80, and calcium salts, optimized for pH and stability, to maintain physical and chemical stability and biological activity, including a method for preparing a lyophilized formulation through freeze-drying.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody drugs are formulated for administration, then stability and effectiveness are improved, but complexity of formulation increases
Solution Approach 1:
The formulation is divided into distinct functional components: acetate buffer for pH control, trehalose for stabilization, polysorbate 80 for surfactant protection, and calcium salts for structural integrity. Each component addresses specific stability challenges independently, making the complex formulation manageable through modular design
Solution Approach 2:
The patent specifies precise parameter ranges for each formulation component (e.g., acetate buffer pH 4.8-5.5, trehalose 45-90 mg/ml, calcium salts 4.5-20 mM). By controlling these parameters within defined ranges, the formulation achieves optimal stability while maintaining reproducibility despite the complexity of multiple ingredients
2Quantity of substance
If high concentration of antibody is used, then dosage efficiency is improved, but stability and solubility worsen
Solution Approach 1:
Trehalose acts as a protective intermediary substance that forms a glassy matrix around the antibody molecules at high concentrations (1-120 mg/ml). This matrix prevents protein-protein interactions that lead to aggregation, enabling high antibody concentration while maintaining stability
Solution Approach 2:
The formulation uses small molecules (trehalose, polysorbate 80, calcium salts) that are more stable and easier to handle than the expensive antibody itself. These stable excipients protect the labile antibody, allowing high concentration formulation without compromising overall stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves stable retention of antibody stability and biological activity, suitable for long-term storage and administration, effectively addressing the limitations of existing osteoporosis treatments by promoting bone anabolism and microstructure improvement.
Implementation Method 1
5 mM-30 mM acetate buffer; wherein the pH of the pharmaceutical composition is from 4.8 to 5.5
Implementation Method 2
45 mg/ml-90 mg/ml trehalose; maintain physical and chemical stability and biological activity
Implementation Method 3
0.02 mg/ml-0.8 mg/ml polysorbate 80
Implementation Method 4
including a method for preparing a lyophilized formulation through freeze-drying
Implementation Method 5
4.5 mM-20 mM calcium salt
Data Source
AI summary
The present invention relates to a pharmaceutical composition comprising a SOST antibody or antibody binding fragments thereof in an acetic acid-sodium acetate buffer solution. In addition, the pharmaceutical composition may also comprise a sugar, a nonionic surfactant or other excipients. After stored for several months, the pharmaceutical composition shows good antibody stability.